Connect your AI

Glaukos GKOS Finance Lease Liabilities

Finance Lease Liabilities at other companies

Regeneron PharmaceuticalsREGN

$0-100%

The Cooper Companies, Inc.COO

$1.8M-10.0%

Other financials

Income statement

Revenue$150.6M+41.2%

Gross profit$117.2M+42.4%

Operating income-$19.9M+4.0%

Net income-$19.8M-9.0%

EPS (diluted)-$0.34-6.3%

Balance sheet

Cash & equivalents$104.2M-8.8%

Total debt$105.9M-1.7%

Total equity$670.9M-12.2%

Total assets$893.3M-7.5%

Cash flow

Operating cash flow-$12.5M+32.4%

CapEx$4.0M+104%

Free cash flow-$16.5M+19.4%

Valuation

Market cap$7.68B+12.3%

Enterprise value$7.68B+12.5%

P/S13.9×-3.0×

Profitability

Gross margin78.1%+2.3pp

Operating margin-36.1%+24.3pp

Net margin-34.3%+4.8pp

FCF margin-13.2%-3.9pp

Returns & leverage

Return on equity-26.4%+11.1pp

Debt / equity0.2×0.0×

Current ratio5.4×-1.1×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.

The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's finance lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Glaukos's finance lease liabilities?: Glaukos (GKOS) reported finance lease liabilities of $67.74M in Q1 2026.
How has Glaukos's finance lease liabilities changed year-over-year?: Glaukos's finance lease liabilities decreased by 2.0% year-over-year, from $69.16M to $67.74M.
What is the long-term trend for Glaukos's finance lease liabilities?: Over 5 years (2020 to 2025), Glaukos's finance lease liabilities has grown at a 2.3% compound annual growth rate (CAGR), from $60.69M to $68.11M.
What does finance lease liabilities mean?: Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.